You are here: Industry Insights > Eli Lilly

News List

Mirikizumab Up-Regulates Genes Associated with Mucosal Healing in Ulcerative Colitis for Up to One Year in Phase 2 Study drugs
July 16, 2021
Eli Lilly and Company (NYSE: LLY) announced new Phase 2 data showing that gene expression changes induced by mirikizumab in patients with ulcerative colitis (UC) over a 12-week induction treatment were maintained for up to one year.
Eli Lilly accelerates baricitinib’s availability in India expresspharma
May 07, 2021
Eli Lilly and Company has announced new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world.
Eli Lilly reports increase in first-quarter worldwide revenue pharmaceutical-technology
April 29, 2021
Eli Lilly and Company has reported worldwide revenue of $6.806bn for the first quarter of this year, a 16% rise compared with the same quarter of last year.
SciNeuro and Eli Lilly sign exclusive license agreement for alpha-synuclein in Greater China pharmaceutical-business-review
April 20, 2021
Biopharmaceutical company SciNeuro Pharmaceuticals has signed an exclusive license agreement with Eli Lilly and Company for the development and commercialisation of alpha-synuclein targeted antibody therapies in Greater China.
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint PharmaSources.com
March 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
Eli Lilly announces mid-stage trial success for donanemab in Alzheimer’s pharmatimes
January 14, 2021
Donanemab, an investigational antibody developed by Eli Lilly, has demonstrated positive results in a phase IIa trial in patients with early-stage Alzheimer’s disease (AD).
Lilly to begin pragmatic study of bamlanivimab for COVID-19 in New Mexico pharmaceutical-business-review
December 23, 2020
Eli Lilly and Company announced plans to begin a new pragmatic study of bamlanivimab (LY-CoV555) in high-risk patients with COVID-19, in collaboration with major local institutions in the state of New Mexico.
Lilly to Acquire Prevail Therapeutics in $1B Deal contractpharma
December 16, 2020
Adds a new drug discovery and development modality and creates a gene therapy program anchored by Prevail's portfolio of neuroscience assets.
Data from ACTT-2 Trial of Baricitinib in Hospitalized COVID-19 Patients Supportive of the EUA Published in New England Journal of Medicine prnewswire
December 14, 2020
Eli Lilly and Company and Incyte announced that The New England Journal of Medicine has published peer-reviewed results from the Adaptive COVID-19 Treatment Trial (ACTT-2) sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) ...
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19 worldpharmanews
December 11, 2020
The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's neutralizing antibody bamlanivimab (LY-CoV555) 700 mg.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page